IMA901 Multipeptide Vaccine Randomized International Phase III Trial (IMPRINT): A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. TPS183-TPS183 ◽  
Author(s):  
B. I. Rini ◽  
T. Eisen ◽  
A. Stenzl ◽  
W. Brugger ◽  
T. Weinschenk ◽  
...  
Keyword(s):  
Cancer Vaccine ◽  
Phase Iii ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
First Line ◽  
Phase Iii Trial ◽  
Randomized Controlled ◽  
First Line Therapy ◽  
Line Therapy ◽  
Metastatic Rcc

Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4071-4071 ◽  
Author(s):  
G. Folprecht ◽  
M. T. Seymour ◽  
L. Saltz ◽  
J. Y. Douillard ◽  
R. J. Stephens ◽  
...  
Keyword(s):  
Phase Iii ◽  
First Line ◽  
Younger Patients ◽  
Randomized Controlled ◽  
First Line Therapy ◽  
Line Therapy ◽  
Source Data ◽  
Phase Iii Trials ◽  
Receive Treatment ◽  
Ecog Ps

4071 Background: Irinotecan containing first line therapy has been shown to improve efficacy in first line therapy. Pooled analyses demonstrated that elderly patients benefit in a similar way as younger patients if 5-FU or 5-FU/oxaliplatin is administered as palliative or adjuvant treatment within clinical trials (Sargent, NEJM 2001, Folprecht, Ann Oncol 2004, Goldberg JCO 2006). Methods: We present an updated metaanalysis using source data of randomized trials (Saltz 2000, Douillard 2000, Köhne 2005 [EORTC 40986] and Seymour 2005 [FOCUS]) and compared the efficacy and toxicity in older (=70 years) and younger (<70 years) patients receiving first line 5- FU/FA with or without irinotecan. Randomized patients who did not receive treatment were excluded. Results: A total of 2,691 pts. was enrolled into the analysis ( table 1 ). There was no imbalance regarding risk factors (ECOG PS, WBC, No. of tumor sites, alkal. phosphatase, LDH) between elderly and younger patients. Older and younger patients had significantly improved response rates and PFS with I-FU compared to FU. Younger patients had significantly longer OS with I-FU, older patients a trend to longer OS with I-FU ( table 1 ). I- FU was associated with more grade >= 3 toxicity in the general population, but there were no significant differences regarding toxicity between older and younger patients ( table 1 ). Conclusion: Patients over 70 yrs who are selected for inclusion in phase III trials derive similar benefits from irinotecan-containing chemotherapy, and with similar risks of toxicity, compared with younger patients. [Table: see text] [Table: see text]

CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA1002-CRA1002 ◽  
Author(s):  
Hope S. Rugo ◽  
William Thomas Barry ◽  
Alvaro Moreno-Aspitia ◽  
Alan P. Lyss ◽  
Constance Cirrincione ◽  
...  
Keyword(s):  
Metastatic Breast ◽  
Phase Iii ◽  
First Line ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
First Line Therapy ◽  
Line Therapy ◽  
Locally Recurrent ◽  
Final Text

CRA1002 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document